SIOC English
有机化学
高级检索

有机化学 >

2019 , Vol. 39 >Issue 10: 2958 - 2964

DOI: https://doi.org/10.6023/cjoc201903020

研究简报

奥沙普秦丹皮酚酯的合成及抗炎活性研究

  • 徐学涛 ,
  • 陈洁 ,
  • 林芷晴 ,
  • 李冬利 ,
  • 张焜 ,
  • 盛钊君 ,
  • 王少华 ,
  • 朱顺 ,
  • Abdullah M. Asiri
展开
  • a 五邑大学生物科技与大健康学院 广东江门 529020
    b 兰州大学药学院 兰州 730000
    c 扬子江药业集团江苏紫龙药业有限公司 江苏常州 213100

收稿日期: 2019-03-12

  修回日期: 2019-05-15

  网络出版日期: 2019-05-21

基金资助

广东省教育厅基金(2017KTSCX185);广东省教育厅基金(2017KSYS010);广东省教育厅基金(2016KCXTD005);五邑大学青年团队项目(2016td01);国家自然科学基金(Nos. 21472077);国家自然科学基金(21772071)

收起

Synthesis and Anti-inflammatory Effects of Oxaprozin-Paeonol Ester

  • Xuetao Xu, ,
  • Jie Chen, ,
  • Zhiqing Lin, ,
  • Dongli Li, ,
  • Kun Zhang, ,
  • Zhaojun Sheng, ,
  • Shaohua Wang, ,
  • Shun Zhu, ,
  • Asiri Abdullah M.
Expand
  • a School of Biotechnology and Health Sciences, Wuyi University, Jiangmen 529020, Guangdong, China
    b School of Pharmacy, Lanzhou University, Lanzhou 730000, China
    c Yangtze River Pharmaceutical Group Jiangsu Zilong Pharmaceutical Co., Ltd., Changzhou 213100, Jiangsu, China

Received date: 2019-03-12

  Revised date: 2019-05-15

  Online published: 2019-05-21

Supported by

Project supported by the Department of Education of Guangdong Province(2017KTSCX185);Project supported by the Department of Education of Guangdong Province(2017KSYS010);Project supported by the Department of Education of Guangdong Province(2016KCXTD005);the Youth Team Fund of Wuyi University(2016td01);the National Natural Science Foundation of China(Nos. 21472077);the National Natural Science Foundation of China(21772071)

Fold

摘要

奥沙普秦是临床常用抗炎药物, 口服易造成胃肠穿孔, 与其分子结构中羧酸基团引起的局部刺激密切相关. 丹皮酚是牡丹的有效成分, 有抗炎、抗氧化的功效. 合成了奥沙普秦丹皮酚酯(OPE), 试图在避免胃肠道并发症的同时, 提高其抗炎效果. 通过12-O-十四烷基佛波醇-13-乙酸酯(TPA)诱导的小鼠耳水肿模型评价了OPE的局部抗炎作用. 结果显示局部应用OPE可有效改善TPA诱导的耳廓肿胀, 抗炎效果是奥沙普秦的2倍, 是丹皮酚的4倍. 而且OPE可有效改善耳片组织IL-1β, IL-6和TNF-α的表达, 效果优于奥沙普秦和丹皮酚. 进一步研究显示OPE可通过阻断IκB激酶(IKK)活性来下调kappa-κB (NF-κB)的活性.

关键词： 奥沙普秦; 丹皮酚; 炎症; 耳廓肿胀模型

本文引用格式

徐学涛 , 陈洁 , 林芷晴 , 李冬利 , 张焜 , 盛钊君 , 王少华 , 朱顺 , Abdullah M. Asiri . 奥沙普秦丹皮酚酯的合成及抗炎活性研究[J]. 有机化学, 2019 , 39(10) : 2958 -2964 . DOI: 10.6023/cjoc201903020

Abstract

Oxaprozin is a common anti-inflammatory drug in the clinic. Oral medication of oxaprozin potentially induces the GI perforation, which is caused by the local irritation of its carboxylic acid group. Paeonol is an active ingredient of peony, and has anti-inflammatory and anti-oxidant effects. So oxaprozin-paeonol ester (OPE) was designed to avoid the GI complications and enhence corresponding anti-inflammatory. The topical anti-inflammatory effects of OPE was evaluated in a 12-O-tetradecanoylphorbol-13-acetate (TPA) induced mouse ear edema model. The results showed that topical treatment of OPE could effectively improve the TPA-induced ear edema and its anti-inflammatory effect is 2 times higher than that of oxaprozin and 4 times than that of paeonol. Moreover, OPE treatment could effectively mitigate the expression of IL-1β, IL-6, and TNF-α, and its effect is better than that of oxaprozin or paeonol. Furthor study demonstrated that topical treatment of OPE could obviously down-regulate the activation of factor kappa-κB (NF-κB) by blocking IκB kinase (IKK) activities. Accordingly, OPE might be used as a promising anti-inflammatory agent for inflammation-associated skin diseases.

Key words： Oxaprozin; Paeonol; Inflammatory; Ear edema mode

参考文献

[1] Talaat, R.; El-Sayed, W.; Agwa, H. S.; Gamal-Eldeen, A. M.; Moawia, S.; Zahran, M. A. H. Chem.-Biol. Interact. 2015, 238, 74.
[2] McInnes, I. B.; Schett, G. Nat. Rev. Immunol. 2007, 7, 429.
[3] Shin, J. S.; Choi, H. E.; Kim, S. D.; Lee, Y. S.; Cho, Y. W.; Lee, K. T. Chem. Biol. Interact. 2014, 224, 68.
[4] Wu, J.; Chu, C. C. J. Mater. Chem. B 2013, 1, 353.
[5] Wu, J.; Chu, C. C. Acta Biomater. 2012, 8, 4314.
[6] Rao, P. P. N.; Kabir, S. N; Mohamed, T. Pharmaceuticals 2010, 3, 1530.
[7] Rainsford, K. D.; Whitehouse, M. W . Inflammopharmacology 2006, 14, 150.
[8] Robak, P.; Smolewski, P.; Robak, T . Leuk Lymphoma 2008, 49, 1452.
[9] Macario, A.; Lipman, A. G. Pain Med. 2001, 2, 336.
[10] al-Faks, M. A.; Pugh, M. C. Orthop. Rev. 1995, 21, 558.
[11] Bozic, B. D.; Rogan, J. R.; Poleti, D. D.; Trisovic, N. P.; Uscumlic, G. S. Chem. Pharm. Bull. 2012, 60, 865.
[12] Rainsford, K. D.; Omar, H.; Ashraf, A.; Hewson, A. T. R.; Bunning, A. D.; Rishiraj, R.; Shepherd, P.; Seabrook, R. W . Inflammopharmacology 2002, 10, 185.
[13] Lopes-de-Araújo, J.; Neves, A. R.; Gouveia, V. M.; Moura, C. C.; Nunes, C.; Reis, S . Pharm. Res. 2016, 33, 301.
[14] Peesa, J. P.; Atmakuri, L. R.; Yalavarthi, P. R.; Venkata, B. R. M.; Rasheed, A.; Pachava, V. Arch. Pharm. Chem. Life Sci. 2017, 351, e1700256.
[15] Dallegri, F.; Bertolotto, M.; Ottonello, L. Exp. Opin. Ther. 2005, 1, 777.
[16] Peesa, J. P.; Yalavarthi, P. R.; Rasheed, A.; Mandava, V. B. J. Acute Dis. 2016, 1, 364.
[17] Bandgar, B. P.; Sarangdhar, R. J.; Viswakarma, S.; Ahamed, F. A. J. Med. Chem., 2011, 1, 1191.
[18] Chou, T. C. Br. J. Pharmacol. 2003, 139, 1146.
[19] Huang, T. J.; Chuang, H.; Liang, Y. C.; Lin, H. H.; Horng, J. C.; Kuo, Y. C.; Chen, C. W.; Tsai, F. Y.; Yen, S. C.; Chou, S. C.; Hsu, M. H. Eur. J. Med. Chem. 2015, 90, 428.
[20] Nizamutdinova, I. T.; Jin, Y. C.; Kim, J. S.; Yean, M. H.; Kang, S. S.; Kim, Y. S.; Lee, J. H.; Seo, H. G.; Kim, H. J.; Chang, K. C. Planta Med. 2008, 74, 8.
[21] Huang, L.; Zhang, B.; Yang, Y.; Gong, X.; Chen, Z.; Wang, Z.; Zhang, P.; Zhang, Q. Bioorg. Med. Chem. Lett. 2016, 26, 5218.
[22] Zhang, H.; Chen, S.; Deng, X.; Yang, X.; Huang, X. Diabetes Res. Clin. Pract. 2006, 74, 194.
[23] Nizamutdinova, I. T.; Oh, H. M.; Min, Y. N.; Park, S. H.; Lee, M. J.; Kim, J. S.; Yean, M. H.; Kang, S. S.; Kim, Y. S.; Chang, K. C.; Kim, H. J. Int. Immunopharmacol. 2007, 7, 343.
[24] Jin, X.; Wang, J.; Xia, Z. M.; Shang, C. H.; Chao, Q. L.; Fan, H. Y.; Chen, D. Q.; Qiu, F.; Zhao, F . Inflammation 2016, 39, 434.
[25] Wu, P. P.; He, H.; Hong, W. D.; Wu, T.; Huang, G.; Zhong, Y.; Tu B.; Gao, M.; Zhou, J.; Zhao, S.; Li, D.; Xu, X. T.; Sheng, Z.; Ward, S. A.; O'Neill, P. M.; Zhang, K. Infect. Drug Resist. 2018, 11, 1945.
[26] Xu, L.; Mou, X. Q.; Chen, Z. M.; Wang, S. H. Chem. Commun. 2014, 50, 10676.
[27] Hernández, V.; Má?ez, S.; Recio, M. C.; Giner, R. M.; Ríos, J. L. Eur. J. Pharm. Sci., 2005, 26, 162.
[28] Mehrotra, A.; Shanbhag, R.; Chamallamudi, M. R.; Singh, V. P.; Mudgal, J. Eur. J. Pharm. 2011, 666, 80.
[29] Hernández, I.; Márquez, L.; Martínez, I.; Dieguez, R.; Delporte, C.; Prieto, S.; Molina-Torres, J.; Garrido, G. J . Ethnopharmacol. 2009, 124, 649.
[30] Xu, X. T.; Mou, X. Q.; Xi, Q. M.; Liu, W. T.; Liu, W. F.; Sheng, Z. J.; Zheng, X.; Zhang, K.; Du, Z. Y.; Zhao, S. Q.; Wang, S. H. Bioorg. Med. Chem. Lett. 2016, 26, 5334.
[31] Xu, X. T.; Huang, D. Y.; Liu, W. F.; Sheng, Z. J.; Liang, K. Y.; Li, D. L.; Zhao, D.; Ma, Y.; Zhang, K.; Hayat, T.; Alharbif, N. S.; Li, W. K. RSC Adv., 2017, 7, 34699.
[32] Rao, T. S.; Currie, J. L.; Shaffer, A. F.; Isakson, P. C . Inflammation 1993, 17, 723.
[33] Hauser, C.; Dayer, J. M.; Jaunin, F.; de Rochemonteix, B.; Saurat, J. H. Cell. Immunol. 1986, 100, 89.
[34] Kock, A.; Schwarz, T.; Kirnbauer, R.; Urbanski, A.; Perry, P.; Ansel, J. C.; Luger, T. A. J. Exp. Med. 1990, 172, 1609.
[35] Kupper, T. S.; Ballard, D. W.; Chua, A. O.; McGuire, J. S.; Flood, P. M.; Horowitz, M. C.; Langdon, R.; Lightfoot, L.; Gubler, U. J. Exp. Med. 1986, 164, 2095.
[36] Singh, S.; Aggarwal, B. B. J. Biol. Chem. 1995, 270, 10631.
[37] Han, S. S.; Keum, Y. S.; Seo, H. J.; Chun, K. S.; Lee, S. S.; Surh, Y. J. Cancer Lett. 2001, 164, 119.
[38] Kim, S. O.; Kundu, J. K.; Shin, Y. K.; Park, J. H.; Cho, M. H.; Kim, T. Y.; Surh, Y. J . Oncogene 2005, 24, 2558.
[39] Zandi, E.; Rothwarf, D. M.; Delhase, M.; Hayakawa, M.; Karin, M . Cell 1997, 91, 243.
[40] Li, Z. W.; Chu, W.; Hu, Y.; Delhase, M.; Deerinck, T.; Ellisman, M.; Johnson, R.; Karin, M. J. Exp. Med. 1999, 189, 1839.
[41] Karin, M.; Delhase, M . Semin. Immunol. 2000, 12, 85.
[42] Carpenter, C. L.; Cantley, L. C. Curr. Opin. Cell Biol. 1996, 8, 153.
[43] Karin, M . Oncogene 1999, 18, 6867.
[44] Shimamura, H.; Terada, Y.; Okado, T.; Hiroyuki, T.; Inoshita, S.; Sadak, S. J. Am. Soc. Nephrol. 2003, 14, 1427.
[45] Selvaraj, S. K.; Giri, R. K.; Perelman, N.; Johnson, C.; Malik, P.; Kalra, V. K . Blood 2003, 102, 1515.
[46] Hatcher, H.; Planalp, R.; Cho, J.; Torti, F. M.; Torti, S. V. Cell. Mol. Life Sci. 2008, 65, 1631.
[47] V. Stefano, D. M. Paolo, S. Rossana and L. Luisa , J. Drugs Dermatol. 2009, 8, 537.
[48] Liu, W. F.; Li, Y. L.; Zhang, K.; Du, Z. Y. Food Funct. 2015, 6, 3712.
[49] Liu, W. F.; Li, Y. L.; Zheng, X.; Zhang, K.; Du, Z. Med. Chem. Commun. 2015, 6, 1605.
[50] Liu, W. F.; Li, Y. L.; Yue, Y.; Zhang, K.; Chen, Q.; Wang, H. Q.; Lu, Y. J.; Huang, M. T.; Zheng, X.; Du, Z. Y. Bioorg. Med. Chem. Lett. 2015, 25, 3044.
[51] Kraan, M. C.; Haringman, J. J.; Ahern, M. J.; Breedveld, F. C.; Smith, M. D.; Tak, P. P . Rheumatology 2000, 39, 43.
[52] Ouyang, N.; Williams, J. L.; Tsioulias, G. J.; Gao, J. J.; Iatropoulos, M. J.; Kopelovich, L.; Kashfi, K.; Rigas, B . Cancer Res. 2006, 66, 4503.
Options
文章导航

/

〈 〉